This seminar provides an overview of some research areas of Sam Hollingworth in the School of Pharmacy. Firstly, a look at medicines use and adverse events using PBS data and other sources. Secondly, an exploration of how we can use routinely-collected data to see if we are getting the benefits from expensive medicines such as those used in cancer in the real world compared you what we see in randomised clinical trials. Thirdly, we’ll look at some newer models of delivery health care in the community and whether they are cost effective. Finally, we’ll explore how low and middle-income countries can use health technology assessment to help them on the journey to universal health coverage.
Sam is an academic in the School of Pharmacy, University of Queensland. She has an active interest in health systems and health services research. Sam works on health technology assessment (HTA) and economic evaluations with a particular focus on low and middle-income countries (LMIC) and non-communicable diseases (NCD). Sam worked as a consultant in health technology assessment (HTA) in Australia for many years evaluating submissions to subsidise medicines on the Pharmaceutical Benefits Scheme (PBS). The other focus of her research is pharmacoepidemiology - the use of medicines in populations. She works with an extensive network of clinicians and health professionals to investigate the use of medicines and adverse effects in general practice, cancer, psychiatry, neurology, and internal medicine. She has worked on international health projects in Indonesia and is currently working on several projects in HTA and medicines use in Ghana and sub-Saharan Africa.